Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

• Status: Completed
• Trial end date: 2007-01-17
• Target enrollment: 0
• Participant gender: All

Summary

The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Japan Co. Ltd.; UCB Pharma
• Treatments: Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059

• Patients/the parent or guardian wish to continue treatment with L059 and to enter N165 Follow-up Study, and also the investigator admit the necessity of the repeated intake of the investigational drug for the patients.

Exclusion Criteria:

• Patients who had not participate in N165 Clinical Trial of L059.

• Patients who had participated in N165 Clinical Trial of L059 with no intention of entering the follow-up study taking the same medication.

• Patients had not been in compliance with requirements of Protocol for N165 Clinical Trial of L059 in the course of the study.